Barclays cuts rating as rally compresses upside
Barclays has downgraded Evonik Industries AG to "equal weight" from "overweight" and simultaneously increased its price target to €18 from €17. The firm said the move reflects a view that recent stock appreciation has largely absorbed the near-term earnings gains signposted by the company.
Quarterly performance and guidance
Evonik posted first-quarter EBITDA of €475 million, a result Barclays notes was 6% ahead of consensus estimates. Management also guided to second-quarter EBITDA of at least €550 million, indicating a clear step-up in the company’s run-rate into the period.
In response to the results and outlook, Barclays raised its full-year 2026 EBITDA projection by 4% to €1.97 billion. That revised figure approaches the top end of Evonik’s company guidance range of €1.70-2.00 billion and sits 1% below Bloomberg consensus, according to Barclays. The bank’s own estimate for second-quarter EBITDA is €555 million, which Barclays reports is also 1% below Bloomberg consensus.
Valuation approach and earnings trajectory
Barclays applies a 12x multiple to FY2027 estimated earnings per share, consistent with the company’s five-year average. The broker’s adjusted EPS forecasts are €1.22 for 2026, €1.54 for 2027 and €1.67 for 2028. Barclays cautioned that the near-term earnings momentum appears to be reflected in Evonik’s valuation, noting the shares are trading above their last five-year average forward price-to-earnings multiple.
Relative share performance
Since the onset of supply disruptions, Evonik’s stock has climbed 22%. Barclays contrasts that with an approximate 7% rise for diversified chemicals peers when excluding AkzoNobel, and a roughly 4% rise when AkzoNobel is included.
Commodity exposure and upside risk
Barclays highlights a pronounced upside sensitivity from current methionine spot prices. If those prices were marked to market, Barclays estimates methionine would contribute roughly €900 million to EBITDA versus the €60 million currently embedded in the bank’s model, a difference the bank describes as highlighting substantial upside risk to estimates.
However, Barclays warned this calculation does not factor in potential offsets such as higher energy and raw material costs or volume effects stemming from force majeure events and planned maintenance.
Downside and bull cases
Management has flagged second-half risks tied to pre-buying that could unwind and lead to destocking, a point Barclays emphasizes when outlining scenario outcomes. In a bull case, Barclays projects 2026 EBITDA of approximately €2.17 billion, implying a valuation near €22 per share. Under a downside scenario, Barclays models EBITDA around €1.85 billion, which would imply a fair value near €16 per share.
Industry stance and closing note
Barclays maintains a Negative industry view on European Chemicals and Ingredients. The bank also disclosed that Barclays Capital Inc. and affiliates have received compensation for investment banking services from Evonik in the past 12 months.
This analysis lays out Barclays’ recalibrated view of Evonik in light of recent operational beats, upgraded near-term guidance and the investor response that has narrowed immediate upside potential.